Wei Kang sat in his office, looking at the lab report in front of him, his brows furrowed.
The Phase III clinical trial report for the Thalassemia Gene Drug has finally been released.
The data is perfect; all patients achieved great success with their first treatment.
The patients in the Phase I have already received a second treatment, and their Hemoglobin have remained normal for a long time.
This means that the patient's Thalassemia has been completely cured, and a third treatment may not be necessary.
There are more than 500 patients in the three stages of the disease in China and the Eagle Country combined, and another 500 patients in the first and second stages.
This brings the total number of participants in the clinical trial to over 1,000, fully meeting the FDA's requirements for fast-track application of new drugs.
Three Purities will soon announce the official launch of this drug in the Eagle Country.
As for China, the process will be a bit slower, but it's estimated that it will be able to get approval and go public in another month or two.
However, Wei Kang was still a little worried. He wanted to ensure that there would be no problems before the company went public.
This new drug launch was so successful that not only did the painkiller go smoothly to market in the Eagle Country, but it also sold extremely well.
Appointments for the new thalassemia drug at major hospitals in the Eagle Country are already booked for three months in advance.
Everything looked perfect, just waiting for the IPO.
After thinking for a long time, Wei Kang retrieved the patent information from his computer.
There is no problem that the Thalassemia Gene Drug has been registered with relevant patents in China and the Eagle Country.
As for the Patent Rights of CRISPR Gene Editing Technology, the China Intellectual Property Office granted it to a research team at the University of California, namely the team of Nobel Prize laureate Dr. Doudna.
The Europa Patent Office also granted the University of California's patent for this broad-based claim.
It is clear that the University of California owns the patent rights to this Gene Editing Technology.
Therefore, Three Purities also contacted the University of California team during the new drug approval process and obtained their patent license.
For academic researchers, as long as they do not profit from this achievement, they can use this technology without hindrance.
However, for commercial entities, obtaining patent licenses is quite expensive, and an agreement must be reached with the patent owner.
Three Purities has already taken this into account, and after obtaining the patent license, it has already negotiated the price with Dr. Doudna's team.
However, this patent seems to be in trouble in the Eagle Country, where it has become embroiled in a protracted patent battle.
Here's what happened: In 2012, after the University of California team published a paper in the journal Science showing that the "Gene Magic Scissors" CRISPR-Cas9 could precisely cut DNA in a test tube, they hadn't yet had time to apply for a patent with the Eagle Country Patent Office.
Another institution took action immediately. Zheng Feng Team at the Broad Institute took the lead in realizing Gene Editing in human cells using this technology and quickly applied for a patent.
Although both teams filed their patent applications around the same time, the Broad Institute was granted the first patent for using the CRISPR system to edit eukaryotic cells because it applied for the fast track.
Meanwhile, the University of California's patent application for CRISPR-Cas9, which can be used to edit all types of cells, including bacteria, plants, animals, and humans, has been delayed and even faces rejection.
The University of California did not give up easily; they have been fighting a lawsuit with the Broad Institute over patent ownership.
After Doudna's team won the Nobel Prize, they also established their status as legitimate inventors.
They received support and Patent Rights from patent offices in China and Europa.
Only in the Eagle Country have the two sides become mired in Patent Dispute, unable to reach a conclusion for a long time.
The latest news is that the Eagle Country Patent Office rejected the University of California's application and granted the Patent Rights for CRISPR to the Broad Institute. However, the University of California is clearly not satisfied and is already preparing a major move.
It is said that they are preparing to seek legal solutions to the ruling of the Eagle Country Patent Office, especially after obtaining patent licenses from China and Europa, which gives them even more confidence. They are currently appealing to the Eagle Country Federal Court.
It is clear that the interests involved in CRISPR Gene Editing Technology are enormous, and neither of these two teams will give up.
The Doudna team at the University of California has the support of Europa, while the Broad Institute is backed by the interest groups of the Eagle Country.
The two sides fought fiercely to the death, and it seems that they have reached a stalemate. It will be difficult to determine a winner in the short term.
Therefore, many businesses that need this technology patent license are quietly waiting for the final result.
Other regions are easier to handle. Patent offices in countries like China and Europa Patent Office have already decided on patent ownership long ago, so for patent authorization in these countries and regions, you can directly contact the University of California team.
However, in the Eagle Country, the war is raging, and it is temporarily impossible to determine which side to side to support.
What if one party obtains a patent license and the other party wins the case?
Wouldn't it be like trying to draw water with a bamboo basket—all for nothing?
Therefore, no one dared to make any rash moves for the time being, and the Three Purities Ones were no exception.
We can only take it one step at a time. If either party has any objections, we'll just have to wait for them to come to us.
After all, nobody wants to pay two patent licensing fees at the same time.
Wei Kang rubbed his temples, finally feeling relieved.
It should be fine. It's completely legal and compliant; there shouldn't be any problems.
If there really is a problem, it's not his problem.
The following day, Three Purities officially announced the launch of its thalassemia Gene Drug in the Eagle Country.
The price is consistent with Three Purities's consistent style; it's expensive, to say the least.
However, this did not have a significant impact on the influx of patients.
Previously, Three Purities had already launched Gene Drug in the Eagle Country, such as SMA and Menkes Gene Therapy, each priced at $300,000.
Although the price of Thalassemia Gene Drug has risen to $500,000 due to the complexity of the technology.
But compared to the cost of bone marrow transplants in the Eagle Country, which can easily reach two or three million US dollars, this price is quite reasonable.
On the contrary, netizens in the Eagle Country have been praising the Three Purities online.
Twitter, Facebook, and other platforms are filled with praise for the Three Purities Ones.
"Thank God, I can finally be a normal person and I don't have to go for blood transfusions every week anymore."
"Everyone says that China companies are price killers, and they're right. Three Purities is truly a breath of fresh air among pharmaceutical companies, charging very fair prices."
"I have already booked treatment with Three Purities Gene Drug at the hospital. The entire treatment process will last one or two months, but the price is still affordable. My insurance can reimburse 70% of the cost. $150,000 can buy me a healthy body. This is the most worthwhile money I have ever spent."
"The guy upstairs must have a great job. I'm so envious."
"Since Three Purities began developing Gene Drug, I have never seen a drug with a price tag of over a million US dollars. This is truly a cause for celebration for patients worldwide."
"Do you think that if Three Purities becomes the world's number one pharmaceutical company, we can be freed from the hell of expensive drugs?"
"It is very likely that it will be a blessing for all mankind, and we will enter heaven completely."
******
"Heh, foolish humans, they're a bunch of idiots. They've won over a lot of people with just a little bit of kindness."
Saul was so angry that his beard trembled as he looked at the praise for the Three Purities on the internet.
Unfortunately, these exaggerated praises are everywhere on the internet; anyone who goes online will see them and there's no way to avoid them.
He quickly made a phone call.
"How's the evidence collection going on your end?"
"It went very smoothly. The hospital retained some Gene Drug as evidence, including the presence of CRISPR-Cas9 preparations. The evidence is conclusive and sufficient to file a lawsuit."
"Hehe, no rush. Let's talk about it after the first batch of patients finish their treatment and pay the bill."
"Clear."
"The patent stick in my hand is already ready to be used."
Saul couldn't help but let out a strange laugh, the sound extremely pleasant.
He seemed to see the Three Purities vanish into thin air under a single iron fist.
Like a delicate and beautiful young girl, she was brutally violated by thugs.
Having stayed in this position for a long time, he has developed an innate, almost fanatical zeal for destroying anything beautiful.
The more enthusiastic the netizens' praise for the Three Purities, the stronger the pleasure derived from destroying them becomes.